Observation on Therapeutic Effect of Xiaoyi Zhixie Pill(消翳止泻丸)on Ulcerative Colitis Patients of Spleen-Kidney Yang Deficiency Type and Impacts on Serum Inflammatory Factors
Objective:To explore the clinical therapeutic effect of Xiaoyi Zhixie Pill on ulcerative colitis of spleen-kidney yang deficiency type and influences on serum inflammatory factors.Methods:64 patients with ulcerative colitis of spleen-kidney yang deficiency type were selected from the outpatient clinic of Ningxia Hos-pital of Chinese Medicine from June 2022 to June 2023.Patients were randomly allocated into two groups(the control group and the observation group)at a 1:1 ratio,with each group comprising 32 individuals.The control group was treated with oral Mesalazine enteric coated tablets,while the observation group was given oral Xiaoyi Zhixie pill,both the two groups were treated for 30 days.Compare the clinical efficacy of the two group,and the changes of clinical symptom scores,serum inflammatory factors(IL-6、IL-8、TNF-α)levels,and changes in electronic colonoscopy scores between the two groups of patients before and after treatment.Results:After 30 days of treatment,the observation group achieved a total effective rate of 93.8％,which was higher than 75.0％in the control group(P＜0.05).Compared with before treatment,after 30 days of treatment,the clinical symp-tom scores such as diarrhea,abdominal pain,mucus stools,abdominal distension,cold limbs,electronic colonoscopy scores,as well as serum IL-6,IL-8 and TNF-α levels in patients of the two groups were lo-wered(P＜0.05),all above changes in the observed were more significant than those in the control group(P＜0.05).Conclusion:Xiaoyi Zhixie Pill can effectively alleviate clinical symptoms of ulcerative colitis patients with spleen-kidney yang deficiency syndrome,regulate serum inflammatory factor levels,improve colonic muco-sal lesions.
ulcerative colitisspleen-kidney yang deficiency typeXiaoyi Zhixie PillMesalazineelectronic colonoscopy scoresIL-6IL-8TNF-α
NETL
NSTL
万方数据
